There is no single owner of the patent for dronabinol (synthetic-tetrahydrocannabinol or THC). Because it was first approved in 1985 (as Marinol), original patents have expired, leading to various patent holdings on specific formulations, manufacturing methods, and uses by several different pharmaceutical companies.
Key entities holding patents or rights related to dronabinol include:
• Alkem Laboratories (via AbbVie): Acquired assets related to the brand-name drug Marinol, including patents, trademarks, and FDA registrations, according to a 2019 report.
• RespireRx Pharmaceuticals Inc. (via ResolutionRx): Holds exclusive licenses and owns patents/patent applications for the use of dronabinol to treat sleep-related breathing disorders (obstructive sleep apnea) and has filed for patents on novel lipid-based formulations to improve solubility.
• Noramco: A leading provider of controlled substances that supplies dronabinol API (active pharmaceutical ingredient) and has worked on proprietary formulations.
• Rhodes Technologies: Holds patents related to methods for increasing the stability of dronabinol.
• Insys Therapeutics: Previously held patents on room-temperature stable and aqueous dronabinol formulations (e.g., US8222292B2).
Additionally, the U.S. government (represented by the Department of Health and Human Services) holds a widely cited patent (US6630507) related to the use of cannabinoids as antioxidants and neuroprotectants.
AI
Market Data 
Markets 
